Our Pipeline

Sardocor is advancing a pipeline of disease-modifying gene therapies and small molecule candidates developed by our team. These candidates are designed to target a range of prevalent and rare cardiac, pulmonary and vascular diseases that have significant unmet needs and no approved treatments that address the underlying molecular cause of the disease. Our pipeline includes programs that have emerged from our internal discovery and validation, as well as programs originally based on scientific research from leading academic institutions. We retain exclusive worldwide development and commercialization rights to all our product candidates and programs.